Literature DB >> 6279498

Dopaminergic modulation of pressor and hormonal responses in essential hypertension.

J R Sowers, M S Golub, M E Berger, L A Whitfield.   

Abstract

Hormonal and mean arterial pressure (MAP) responses to posture, isometric handgrip, angiotensin II (AII), adrenocorticotrophic hormone (ACTH), and metoclopramide (MCP), a dopamine (DA) antagonist, were examined in nine men with essential hypertension and nine age- and weight-matched normotensive men on a constant 100 mEq sodium and 80 mEq potassium intake before and after 4 days of administration of the DA agonist, bromocriptine (BEC; 2.5 mg three times a day). BEC depressed supine basal MAP in the hypertensives, and decreased MAP response to posture and isometric exercise in both groups. Hypertensives displayed greater (p less than 0.01) NE responses to posture and exercise than the normotensives. BEC decreased the NE response to 10 minutes of upright posture and exercise more in hypertensives (p less than 0.01) than in normotensives, but following BEC, the responses were similar. BEC did not affect basal PRA or PRA responses to posture and exercise in the two groups. PA responses to ACTH and MCP were similar in both groups, but the hypertensives displayed greater (p less than 0.01) PA responses to AII. BEC suppressed PA responses to AII (p less than 0.01) and to high dose ACTH (p less than 0.05) to a similar extent in both groups. The prolactin as well as the PA response to DA antagonism with MCP was similar in the two groups. These results suggest that dopaminergic control of NE secretion may be altered in essential hypertension. Blood pressure lowering effects of BEC in patients with essential hypertension may be related, in part, to depression of sympathetic nervous system activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6279498     DOI: 10.1161/01.hyp.4.3.424

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

1.  Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

Authors:  C de Mey; D Enterling; I Meineke; S Yeulet
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

2.  Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.

Authors:  G Bise; C Foletti; C Beretta-Piccoli; P Weidmann; W H Ziegler; R Mordasini; C Bachmann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.

Authors:  Bindu Chamarthi; J Michael Gaziano; Lawrence Blonde; Aaron Vinik; Richard E Scranton; Michael Ezrokhi; Dean Rutty; Anthony H Cincotta
Journal:  J Diabetes Res       Date:  2015-04-28       Impact factor: 4.011

4.  Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Authors:  J Michael Gaziano; Anthony H Cincotta; Aaron Vinik; Lawrence Blonde; Nancy Bohannon; Richard Scranton
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.